Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
|Videos|December 15, 2020
Nadofaragene firadenovec and the future of NMIBC care
Author(s)Urology Times staff
Dr. Vikram M. Narayan describes treatment advances and next steps in non-muscle invasive bladder cancer.
Advertisement
Vikram M. Narayan, MD, of Emory University, Winship Cancer Institute, Atlanta, GA, discusses next steps with the novel intravesical gene-mediated therapy nadofaragene firadenovec and the overall future of the treatment paradigm for patients with non-muscle invasive bladder cancer (NMIBC).
Narayan says there are promising options, such as nadofaragene firadenovec, emerging for patients with BCG-unresponsive NMIBC. Some of the next steps, according to Narayan, are exploring combination regimens, assessing sequencing strategies, and developing biomarkers to determine which patients might respond best to treatments.
Advertisement
Related to this article
A decision is expected by the fourth quarter of 2026.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Eugene Cone, MD, discusses the impact of ongoing BCG supply challenges and the potential role of alternative and recombinant strains for NMIBC care.
All patients have been treated in the phase 3 ENLIGHTED trial, evaluating padeliporfin VTP for low-grade upper tract urothelial carcinoma.
John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.
Dabogratinib showed early activity and manageable safety in FGFR3-altered LG-IR-NMIBC, supporting advancement to a planned registrational study in the adjuvant setting.
Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
Advertisement
Advertisement
Trending on Urology Times
1
Evidence for Combining Prostatic Urethral Lift With Radiotherapy
2
FDA grants breakthrough device designation to urine ID/AST panel
3
Use of prebiopsy prostate MRI increasing across US hospitals, study finds
4
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
5